Neurocrine Biosciences INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
JPMorgan Chase & Co. has filed a Schedule 13G, reporting beneficial ownership of 6.3% of Neurocrine Biosciences, Inc. common stock as of June 30, 2026.
NASDAQ
Vanguard Capital Management has reported a beneficial ownership of 5.23% in Neurocrine Biosciences Inc. common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has filed an amendment to its Schedule 13G, reporting zero beneficial ownership in Neurocrine Biosciences Inc. following an internal realignment.
NASDAQ
JPMorgan Chase & Co. has reported a 5.2% beneficial ownership stake in Neurocrine Biosciences, Inc. common stock as of December 31, 2025.
NASDAQ
Investment adviser Dodge & Cox has filed a Schedule 13G, revealing a 5.6% beneficial ownership stake in Neurocrine Biosciences, Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 12.1% Stake in Neurocrine Biosciences
BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 12.1% in Neurocrine Biosciences Inc.'s common stock as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: Vanguard Group Discloses 10.15% Stake in Neurocrine Biosciences
The Vanguard Group has filed an amended Schedule 13G, revealing a beneficial ownership of 10.15% in Neurocrine Biosciences Inc.'s common stock as of February 28, 2025.
NASDAQ
State Street Corporation has reported a passive beneficial ownership of 4.8% in Neurocrine Biosciences Inc., holding 4,891,137 shares of common stock as of December 31, 2024.